In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including: Mechanistic differences between CELMoDs and IMiDs Emerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma The clinical implications of MRD negativity as a surrogate marker of long-term outcomes in clinical trials in multiple myeloma Presenters: Jesus Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research Tennessee Oncology Nashville, Tennessee Amrita Krishnan, MD, FACP Director, Judy and Bernard Briskin Center for Myeloma Executive Director of Hematology City of Hope Orange County Professor of Hematology/HCT City of Hope Cancer Center Irvine, California Sagar Lonial, MD, FACP Chair and Professor Department of Hematology and Medical Oncology Anne and Bernard Gray Family Chair in Cancer Chief Medical Officer Winship Cancer Institute Emory University Atlanta, Georgia Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb. Link to full program: https://bit.ly/3IwbslQ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
